The underlying pathophysiological determinants of asthma and chronic obstructive pulmonary disease (COPD) are related in complex ways. Importantly however, post-bronchodilator FEV1-reversibility may occur in approximately 50% of COPD patients  whilst epidemiological  and magnetic-resonance-imaging (MRI) studies  suggest that in asthmatics, FEV1-reversibility may diminish over time. As compared to patients with asthma or COPD alone, patients with co-existing asthma and COPD report worse clinical outcomes  and increased healthcare costs  and burden [4, 5].
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Serajeddini has nothing to disclose.
Conflict of interest: Ms. Eddy has nothing to disclose.
Conflict of interest: Dr. Licskai has nothing to disclose.
Conflict of interest: Dr. McCormack has nothing to disclose.
Conflict of interest: Dr. Parraga has nothing to disclose.
- Received October 2, 2019.
- Accepted November 22, 2019.